Latest news
January 7, 2009, 4:16 am
|
|
Vitamin E Supplements May Raise Lung Cancer Risk
Vitamin E Supplements May Raise Lung Cancer Risk. FRIDAY, Feb. 28 -- Vitamin supplements won't protectpeople against lung cancer and taking vitamin E may even heighten therisk, a new study finds. Cultural practices buttress Sierra Leone poverty: U.N.. Harmful cultural practices such as female genital mutilation are hampering efforts to reduce poverty in Sierra Leone, which has the world's worst child and maternal mortality rates, a top U.N. official said. UK lawmakers urge action to cut childbirth deaths. Hundreds of thousands of women in poor countries die each year during pregnancy or childbirth from largely avoidable causes, British lawmakers said on Sunday.
Study finds dogs, robots cheer elderly
Study finds dogs, robots cheer elderly. Dogs may have a hard time wrapping their paws around this one: Robotic competition is nipping at their heels in the mans-best-friend department. A study by Saint Louis University found that a lovable pooch named Sparky and a robotic dog, AIBO, were about equally effective at relieving the loneliness of nursing home residents and fostering attachments. ADHD Drugs Won't Raise Risk of Substance Abuse. SATURDAY, March 1 -- Parents of children who areprescribed psychostimulants for attention deficit-hyperactivity disorder might have one less thing to worry about now that a new studyconcludes these kids are no more likely than their peers to abuse drugsand alcohol as young adults.
Recent Studies Of Vytorin,
Recent Studies Of Vytorin, Avandia Prompt Debate About FDA Approval Process For New Medications. Recent studies that raised questions about the benefits of the cholesterol medication Vytorin, manufactured by Merck and Schering-Plough, and the. Diet change gives hyperactive kids new taste for life in Norway. Tears streak Rita s cheek as she recalls what it was like trying to figure out what was wrong with her son more than a decade ago, but she breaks into a smile when she explains how changing his diet made all the difference. Merck, Schering-Plough Offer Explanation For Delay In Release Of Vytorin Study Results. Merck and Schering-Plough recently offered a detailed explanation of their decision to delay the release of the results of a study of the cholesterol medication Vytorin, the Wall Street Journal reports. The study, called Enhance, ended in April 2006, but the companies did not release the results until Jan. Seasonal Weight Changes Linked To Metabolic Syndrome. Seasonal changes in weight increase the risk for metabolic syndrome, a group of scientists from National Public Health Institute, Helsinki, Finland, reports in a study published in the January 23 issue of the online, open-access journal PLoS ONE.This finding was based on analysis of 8,028 individuals, representative of the general population aged over 30, who attended a nationwide health examination survey. FDA Issues Early Communication About An Ongoing Review Of Vytorin. The U.S. Food and Drug Administration issued an Early Communication regarding the agency's ongoing review of Vytorin based on preliminary results from a recently completed study - the Effect of Combination Ezetimibe and High-Dose Simvastatin vs. Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia - on this cholesterol lowering drug. Vytorin contains both Zetia and Zocor in one tablet. Low-fat dairy may help control blood pressure. Women who regularly consume low-fat milk or yogurt may have a lower risk of developing high blood pressure, new research suggests.
We Are What We Eat: Lowering Cholesterol The Old-Fashioned Way
We Are What We Eat: Lowering Cholesterol The Old-Fashioned Way. Recent results from a small clinical trial raised confusing questions about the value of several widely used cholesterol medicines such as Zetia and its sister drug, Vytorin. The future of these drugs now depend on three large clinical trials that may show conclusively if the drugs reduce heart attacks and strokes. Currently underway, these trials are not expected to be completed until 2011. Yet, according to nutrition experts, diet still remains key to lowering cholesterol levels. Ships Ahoy! What do kids who love boats do in the winter? If you are a local Sea Scout, you participate in winter training and practice the skills you'll need when boating season starts again. FDA Issues Early Communication About An Ongoing Review Of Vytorin. The U.S. Food and Drug Administration issued an Early Communication regarding the agency's ongoing review of Vytorin based on preliminary results from a recently completed study - the Effect of Combination Ezetimibe and High-Dose Simvastatin vs. Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia - on this cholesterol lowering drug. Vytorin contains both Zetia and Zocor in one tablet. Merck, Schering-Plough Offer Explanation For Delay In Release Of Vytorin Study Results. Merck and Schering-Plough recently offered a detailed explanation of their decision to delay the release of the results of a study of the cholesterol medication Vytorin, the Wall Street Journal reports. The study, called Enhance, ended in April 2006, but the companies did not release the results until Jan. Toot Sweet: At the Kennedy Center, Flutist James Galway's Easy-Listening Virtuosity. Sir James Galway may be the most famous flutist on the planet; not only does he have a superb technique and gorgeous tone, but he's personable to a fault -- the lovable Irish imp of classical music. His concerts are equally user-friendly, designed to charm the ears rather than provoke the mind...
Kaiser Daily Health Policy Report Highlights Scrutiny Over Benefit Of Using Statins
Kaiser Daily Health Policy Report Highlights Scrutiny Over Benefit Of Using Statins. Two newspapers on Tuesday reported on scrutiny of statin use and whether the drugs provide prolonged life or benefits to patients with high cholesterol. Summaries appear below.New York Times: In the "fallout from the headline-making. Pfizer Announces Plans To End Lipitor Advertising Campaign With Artificial Heart Inventor Jarvik. Pfizer on Monday announced plans to end an advertising campaign for the cholesterol medication Lipitor that features Robert Jarvik, who invented the first artificial heart, amid concerns that the ads might mislead consumers, the. Seasonal Weight Changes Linked To Metabolic Syndrome. Seasonal changes in weight increase the risk for metabolic syndrome, a group of scientists from National Public Health Institute, Helsinki, Finland, reports in a study published in the January 23 issue of the online, open-access journal PLoS ONE.This finding was based on analysis of 8,028 individuals, representative of the general population aged over 30, who attended a nationwide health examination survey. Recent Studies Of Vytorin, Avandia Prompt Debate About FDA Approval Process For New Medications. Recent studies that raised questions about the benefits of the cholesterol medication Vytorin, manufactured by Merck and Schering-Plough, and the. Surface Logix Achieves Objectives With SLx-4090 In Phase 2a Clinical Trial. Surface Logix announced positive results in the Company's Phase 2a clinical trial of SLx-4090 in dyslipidemia. The randomized, double-blind, placebo-controlled Phase 2a study in 24 patients with dyslipidemia demonstrated that SLx-4090 caused clinically significant reductions in postprandial triglycerides and LDL-cholesterol and was well tolerated. Phase 1 Studies Show Promise Of QuatRx's Novel Compound, Sobetirome, For Lowering LDL Cholesterol Levels. QuatRx Pharmaceuticals, a privately-held biopharmaceutical company developing compounds for the treatment of major endocrine, metabolic and cardiovascular diseases, announced results from two Phase 1 clinical studies with its novel lipid lowering compound, sobetirome, in development for the treatment of elevated LDL cholesterol levels.
|
There are latest news |
Face procedures
Body procedures
Contact Plastic Surgery Clinic
Latest news
about beauty
and body improvement